title: A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab.
abstract: Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.
authors.affiliation: Mayo Clinic School of Graduate Medical Education, Mayo Clinic Arizona, Phoenix, Ariz., USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Christiansen
authors.affiliation: Department of Neurology, Mayo Clinic Arizona, Phoenix, Ariz., USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Ingall
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, Ariz., USA.
authors.forename: Edward C
authors.initials: EC
authors.lastname: Lew
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, Ariz., USA.
authors.forename: Ramesh K
authors.initials: RK
authors.lastname: Ramanathan
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, Ariz., USA.
authors.forename: Harshita R
authors.initials: HR
authors.lastname: Paripati
keywords: Adverse effects; Angiogenesis inhibitors; Gastric cancer; Ischemic stroke